nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.141	0.204	CbGbCtD
Sirolimus—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0619	0.0896	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—ankylosing spondylitis	0.0564	0.0816	CbGbCtD
Sirolimus—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0531	0.0769	CbGbCtD
Sirolimus—CYP3A7—Dexamethasone—ankylosing spondylitis	0.0412	0.0596	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.0412	0.0596	CbGbCtD
Sirolimus—ABCB1—Betamethasone—ankylosing spondylitis	0.0346	0.05	CbGbCtD
Sirolimus—ABCB1—Prednisolone—ankylosing spondylitis	0.0341	0.0494	CbGbCtD
Sirolimus—ABCB1—Prednisone—ankylosing spondylitis	0.0322	0.0466	CbGbCtD
Sirolimus—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0318	0.0461	CbGbCtD
Sirolimus—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0309	0.0447	CbGbCtD
Sirolimus—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0241	0.0349	CbGbCtD
Sirolimus—CYP3A4—Betamethasone—ankylosing spondylitis	0.0207	0.03	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—ankylosing spondylitis	0.0204	0.0296	CbGbCtD
Sirolimus—ABCB1—Dexamethasone—ankylosing spondylitis	0.0201	0.0291	CbGbCtD
Sirolimus—CYP3A4—Prednisone—ankylosing spondylitis	0.0193	0.0279	CbGbCtD
Sirolimus—ABCB1—Methotrexate—ankylosing spondylitis	0.0162	0.0234	CbGbCtD
Sirolimus—CYP3A4—Dexamethasone—ankylosing spondylitis	0.012	0.0174	CbGbCtD
Sirolimus—EIF4E—Validated targets of C-MYC transcriptional activation—KIR3DL1—ankylosing spondylitis	0.00475	0.096	CbGpPWpGaD
Sirolimus—FGF2—Integrins in angiogenesis—EDIL3—ankylosing spondylitis	0.00355	0.0717	CbGpPWpGaD
Sirolimus—EIF4E—Hypertrophy Model—IL1A—ankylosing spondylitis	0.00294	0.0594	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.00206	0.0416	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.00196	0.0396	CbGpPWpGaD
Sirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00159	0.0322	CbGpPWpGaD
Sirolimus—EIF4E—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00148	0.03	CbGpPWpGaD
Sirolimus—EIF4E—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00142	0.0287	CbGpPWpGaD
Sirolimus—FGF2—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.0013	0.0262	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00105	0.0211	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000923	0.0186	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—HLA-C—ankylosing spondylitis	0.000852	0.0172	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IL12B—ankylosing spondylitis	0.000685	0.0138	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000585	0.0118	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000569	0.0115	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KIR3DL1—ankylosing spondylitis	0.000564	0.0114	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000521	0.0105	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000516	0.0104	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—HLA-B—ankylosing spondylitis	0.000504	0.0102	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.000499	0.0101	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000494	0.00999	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—IL10—ankylosing spondylitis	0.000488	0.00986	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—CD40LG—ankylosing spondylitis	0.000488	0.00986	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000467	0.00944	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000457	0.00923	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.000441	0.00892	CbGpPWpGaD
Sirolimus—MTOR—Type II diabetes mellitus—TNF—ankylosing spondylitis	0.000425	0.00859	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000418	0.00844	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000383	0.00775	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—B3GNT2—ankylosing spondylitis	0.000378	0.00763	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	0.000369	0.00745	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000356	0.00719	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1R2—ankylosing spondylitis	0.000341	0.0069	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000339	0.00685	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000337	0.0068	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00033	0.00667	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERAP1—ankylosing spondylitis	0.000324	0.00654	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—CD79A—ankylosing spondylitis	0.000322	0.00652	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	0.000322	0.0065	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIR3DL1—ankylosing spondylitis	0.000313	0.00633	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000312	0.0063	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	0.000297	0.006	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000297	0.006	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CARD9—ankylosing spondylitis	0.000296	0.00598	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ANTXR2—ankylosing spondylitis	0.000289	0.00585	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CARD9—ankylosing spondylitis	0.000283	0.00571	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000278	0.00562	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000275	0.00556	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.00027	0.00546	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000254	0.00514	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—CD79A—ankylosing spondylitis	0.000239	0.00483	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000237	0.00478	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIR3DL1—ankylosing spondylitis	0.000232	0.0047	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00022	0.00445	CbGpPWpGaD
Sirolimus—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00022	0.000847	CcSEcCtD
Sirolimus—Infestation—Methotrexate—ankylosing spondylitis	0.00022	0.000846	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00022	0.000846	CcSEcCtD
Sirolimus—FGF2—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.000219	0.00443	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000219	0.000844	CcSEcCtD
Sirolimus—FGF2—Disease—ANTXR2—ankylosing spondylitis	0.000219	0.00443	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000219	0.000842	CcSEcCtD
Sirolimus—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000219	0.000842	CcSEcCtD
Sirolimus—Discomfort—Triamcinolone—ankylosing spondylitis	0.000219	0.000842	CcSEcCtD
Sirolimus—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000218	0.00084	CcSEcCtD
Sirolimus—Angioedema—Betamethasone—ankylosing spondylitis	0.000215	0.00083	CcSEcCtD
Sirolimus—Angioedema—Dexamethasone—ankylosing spondylitis	0.000215	0.00083	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—ankylosing spondylitis	0.000214	0.000824	CcSEcCtD
Sirolimus—Angiopathy—Prednisone—ankylosing spondylitis	0.000214	0.000824	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000213	0.000822	CcSEcCtD
Sirolimus—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000213	0.000822	CcSEcCtD
Sirolimus—Immune system disorder—Prednisone—ankylosing spondylitis	0.000213	0.00082	CcSEcCtD
Sirolimus—Malaise—Betamethasone—ankylosing spondylitis	0.000213	0.000819	CcSEcCtD
Sirolimus—Malaise—Dexamethasone—ankylosing spondylitis	0.000213	0.000819	CcSEcCtD
Sirolimus—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000212	0.000817	CcSEcCtD
Sirolimus—Oedema—Triamcinolone—ankylosing spondylitis	0.000212	0.000817	CcSEcCtD
Sirolimus—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000212	0.000815	CcSEcCtD
Sirolimus—Syncope—Betamethasone—ankylosing spondylitis	0.000211	0.000814	CcSEcCtD
Sirolimus—Syncope—Dexamethasone—ankylosing spondylitis	0.000211	0.000814	CcSEcCtD
Sirolimus—Infection—Triamcinolone—ankylosing spondylitis	0.000211	0.000811	CcSEcCtD
Sirolimus—Sweating—Methotrexate—ankylosing spondylitis	0.000211	0.000811	CcSEcCtD
Sirolimus—Infection—Methylprednisolone—ankylosing spondylitis	0.00021	0.000809	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—CARD9—ankylosing spondylitis	0.00021	0.00424	CbGpPWpGaD
Sirolimus—Haematuria—Methotrexate—ankylosing spondylitis	0.000209	0.000806	CcSEcCtD
Sirolimus—Shock—Triamcinolone—ankylosing spondylitis	0.000209	0.000803	CcSEcCtD
Sirolimus—Insomnia—Prednisolone—ankylosing spondylitis	0.000209	0.000803	CcSEcCtD
Sirolimus—Shock—Methylprednisolone—ankylosing spondylitis	0.000208	0.000802	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000208	0.0008	CcSEcCtD
Sirolimus—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000208	0.000799	CcSEcCtD
Sirolimus—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000207	0.000798	CcSEcCtD
Sirolimus—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000207	0.000798	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—ankylosing spondylitis	0.000207	0.000798	CcSEcCtD
Sirolimus—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000207	0.000797	CcSEcCtD
Sirolimus—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000207	0.000797	CcSEcCtD
Sirolimus—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000207	0.000795	CcSEcCtD
Sirolimus—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000206	0.000791	CcSEcCtD
Sirolimus—Malnutrition—Prednisone—ankylosing spondylitis	0.000205	0.000791	CcSEcCtD
Sirolimus—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000205	0.000789	CcSEcCtD
Sirolimus—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000205	0.000788	CcSEcCtD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000204	0.00413	CbGpPWpGaD
Sirolimus—Hypertension—Dexamethasone—ankylosing spondylitis	0.000204	0.000784	CcSEcCtD
Sirolimus—Hypertension—Betamethasone—ankylosing spondylitis	0.000204	0.000784	CcSEcCtD
Sirolimus—Myalgia—Dexamethasone—ankylosing spondylitis	0.000201	0.000773	CcSEcCtD
Sirolimus—Myalgia—Betamethasone—ankylosing spondylitis	0.000201	0.000773	CcSEcCtD
Sirolimus—MTOR—DAP12 interactions—HLA-B—ankylosing spondylitis	0.0002	0.00405	CbGpPWpGaD
Sirolimus—Anxiety—Dexamethasone—ankylosing spondylitis	0.0002	0.00077	CcSEcCtD
Sirolimus—Anxiety—Betamethasone—ankylosing spondylitis	0.0002	0.00077	CcSEcCtD
Sirolimus—Discomfort—Betamethasone—ankylosing spondylitis	0.000198	0.000764	CcSEcCtD
Sirolimus—Discomfort—Dexamethasone—ankylosing spondylitis	0.000198	0.000764	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000198	0.000763	CcSEcCtD
Sirolimus—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000198	0.000761	CcSEcCtD
Sirolimus—Pain—Prednisolone—ankylosing spondylitis	0.000197	0.000759	CcSEcCtD
Sirolimus—FKBP1A—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000197	0.00399	CbGpPWpGaD
Sirolimus—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000197	0.000759	CcSEcCtD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000196	0.00397	CbGpPWpGaD
Sirolimus—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000196	0.000753	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000195	0.00075	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000193	0.000744	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000193	0.000744	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000193	0.000742	CcSEcCtD
Sirolimus—Oedema—Dexamethasone—ankylosing spondylitis	0.000192	0.000741	CcSEcCtD
Sirolimus—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000192	0.000741	CcSEcCtD
Sirolimus—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000192	0.000741	CcSEcCtD
Sirolimus—Oedema—Betamethasone—ankylosing spondylitis	0.000192	0.000741	CcSEcCtD
Sirolimus—Insomnia—Triamcinolone—ankylosing spondylitis	0.000192	0.000739	CcSEcCtD
Sirolimus—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000191	0.000737	CcSEcCtD
Sirolimus—Infection—Dexamethasone—ankylosing spondylitis	0.000191	0.000736	CcSEcCtD
Sirolimus—Infection—Betamethasone—ankylosing spondylitis	0.000191	0.000736	CcSEcCtD
Sirolimus—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000191	0.000734	CcSEcCtD
Sirolimus—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.00019	0.000733	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00019	0.000732	CcSEcCtD
Sirolimus—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00019	0.000732	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—ankylosing spondylitis	0.00019	0.000732	CcSEcCtD
Sirolimus—Anaemia—Prednisone—ankylosing spondylitis	0.00019	0.000731	CcSEcCtD
Sirolimus—FGF2—Immune System—IL1R2—ankylosing spondylitis	0.00019	0.00384	CbGpPWpGaD
Sirolimus—Shock—Betamethasone—ankylosing spondylitis	0.000189	0.000729	CcSEcCtD
Sirolimus—Shock—Dexamethasone—ankylosing spondylitis	0.000189	0.000729	CcSEcCtD
Sirolimus—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000189	0.000728	CcSEcCtD
Sirolimus—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000189	0.000727	CcSEcCtD
Sirolimus—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000189	0.000727	CcSEcCtD
Sirolimus—Agitation—Prednisone—ankylosing spondylitis	0.000189	0.000727	CcSEcCtD
Sirolimus—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000188	0.000725	CcSEcCtD
Sirolimus—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000188	0.000725	CcSEcCtD
Sirolimus—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000188	0.000723	CcSEcCtD
Sirolimus—Tachycardia—Betamethasone—ankylosing spondylitis	0.000188	0.000723	CcSEcCtD
Sirolimus—Angioedema—Prednisone—ankylosing spondylitis	0.000188	0.000722	CcSEcCtD
Sirolimus—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000187	0.000719	CcSEcCtD
Sirolimus—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000186	0.000717	CcSEcCtD
Sirolimus—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000186	0.000716	CcSEcCtD
Sirolimus—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000186	0.000716	CcSEcCtD
Sirolimus—EIF4E—Immune System—HLA-C—ankylosing spondylitis	0.000186	0.00376	CbGpPWpGaD
Sirolimus—Malaise—Prednisone—ankylosing spondylitis	0.000185	0.000713	CcSEcCtD
Sirolimus—Syncope—Prednisone—ankylosing spondylitis	0.000184	0.000709	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—ankylosing spondylitis	0.000184	0.000708	CcSEcCtD
Sirolimus—Anorexia—Dexamethasone—ankylosing spondylitis	0.000183	0.000706	CcSEcCtD
Sirolimus—Anorexia—Betamethasone—ankylosing spondylitis	0.000183	0.000706	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000183	0.000704	CcSEcCtD
Sirolimus—Pain—Triamcinolone—ankylosing spondylitis	0.000181	0.000698	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000181	0.000695	CcSEcCtD
Sirolimus—FGF2—Immune System—ERAP1—ankylosing spondylitis	0.00018	0.00364	CbGpPWpGaD
Sirolimus—Hypotension—Dexamethasone—ankylosing spondylitis	0.00018	0.000692	CcSEcCtD
Sirolimus—Hypotension—Betamethasone—ankylosing spondylitis	0.00018	0.000692	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—ankylosing spondylitis	0.000179	0.000689	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000178	0.000686	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000178	0.000684	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000177	0.00359	CbGpPWpGaD
Sirolimus—Hypertension—Prednisone—ankylosing spondylitis	0.000177	0.000683	CcSEcCtD
Sirolimus—Chills—Methotrexate—ankylosing spondylitis	0.000177	0.000681	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000175	0.000675	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000175	0.000675	CcSEcCtD
Sirolimus—Myalgia—Prednisone—ankylosing spondylitis	0.000175	0.000673	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—ankylosing spondylitis	0.000175	0.000673	CcSEcCtD
Sirolimus—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000175	0.000673	CcSEcCtD
Sirolimus—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000174	0.000671	CcSEcCtD
Sirolimus—Anxiety—Prednisone—ankylosing spondylitis	0.000174	0.000671	CcSEcCtD
Sirolimus—Insomnia—Betamethasone—ankylosing spondylitis	0.000174	0.00067	CcSEcCtD
Sirolimus—Insomnia—Dexamethasone—ankylosing spondylitis	0.000174	0.00067	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000174	0.00352	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000174	0.000668	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000173	0.000666	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000173	0.0035	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000173	0.0035	CbGpPWpGaD
Sirolimus—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000173	0.000665	CcSEcCtD
Sirolimus—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000173	0.000665	CcSEcCtD
Sirolimus—Discomfort—Prednisone—ankylosing spondylitis	0.000173	0.000665	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—ankylosing spondylitis	0.000172	0.000661	CcSEcCtD
Sirolimus—FKBP1A—Disease—B3GNT2—ankylosing spondylitis	0.00017	0.00345	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00017	0.00344	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00017	0.000654	CcSEcCtD
Sirolimus—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000169	0.000652	CcSEcCtD
Sirolimus—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000169	0.000652	CcSEcCtD
Sirolimus—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000168	0.000646	CcSEcCtD
Sirolimus—Oedema—Prednisone—ankylosing spondylitis	0.000168	0.000645	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000168	0.000645	CcSEcCtD
Sirolimus—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000167	0.000644	CcSEcCtD
Sirolimus—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000167	0.000644	CcSEcCtD
Sirolimus—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000167	0.000644	CcSEcCtD
Sirolimus—Infection—Prednisone—ankylosing spondylitis	0.000167	0.000641	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000166	0.00064	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000166	0.00064	CcSEcCtD
Sirolimus—Back pain—Methotrexate—ankylosing spondylitis	0.000166	0.000639	CcSEcCtD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000165	0.00334	CbGpPWpGaD
Sirolimus—Shock—Prednisone—ankylosing spondylitis	0.000165	0.000635	CcSEcCtD
Sirolimus—Pain—Betamethasone—ankylosing spondylitis	0.000165	0.000634	CcSEcCtD
Sirolimus—Pain—Dexamethasone—ankylosing spondylitis	0.000165	0.000634	CcSEcCtD
Sirolimus—FGF2—Immune System—CARD9—ankylosing spondylitis	0.000165	0.00333	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000164	0.00333	CbGpPWpGaD
Sirolimus—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000164	0.000633	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—ankylosing spondylitis	0.000164	0.00063	CcSEcCtD
Sirolimus—Skin disorder—Prednisone—ankylosing spondylitis	0.000163	0.000627	CcSEcCtD
Sirolimus—MTOR—Disease—ANTXR2—ankylosing spondylitis	0.000163	0.00329	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000162	0.000624	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL1RN—ankylosing spondylitis	0.000161	0.00326	CbGpPWpGaD
Sirolimus—Anorexia—Prednisone—ankylosing spondylitis	0.00016	0.000615	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000159	0.000613	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—ankylosing spondylitis	0.000159	0.000611	CcSEcCtD
Sirolimus—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000159	0.000611	CcSEcCtD
Sirolimus—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000159	0.000611	CcSEcCtD
Sirolimus—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000157	0.000606	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000157	0.000606	CcSEcCtD
Sirolimus—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000156	0.000602	CcSEcCtD
Sirolimus—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000156	0.0006	CcSEcCtD
Sirolimus—Malaise—Methotrexate—ankylosing spondylitis	0.000155	0.000596	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000154	0.00311	CbGpPWpGaD
Sirolimus—Leukopenia—Methotrexate—ankylosing spondylitis	0.000154	0.000591	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000153	0.000588	CcSEcCtD
Sirolimus—Dizziness—Prednisolone—ankylosing spondylitis	0.000153	0.000587	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000152	0.00308	CbGpPWpGaD
Sirolimus—Asthenia—Triamcinolone—ankylosing spondylitis	0.000152	0.000586	CcSEcCtD
Sirolimus—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000152	0.000586	CcSEcCtD
Sirolimus—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000152	0.000586	CcSEcCtD
Sirolimus—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000152	0.000586	CcSEcCtD
Sirolimus—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000152	0.000586	CcSEcCtD
Sirolimus—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000152	0.000585	CcSEcCtD
Sirolimus—Insomnia—Prednisone—ankylosing spondylitis	0.000152	0.000584	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—ankylosing spondylitis	0.000151	0.000579	CcSEcCtD
Sirolimus—Pruritus—Triamcinolone—ankylosing spondylitis	0.00015	0.000578	CcSEcCtD
Sirolimus—Cough—Methotrexate—ankylosing spondylitis	0.00015	0.000577	CcSEcCtD
Sirolimus—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00015	0.000576	CcSEcCtD
Sirolimus—Dyspepsia—Prednisone—ankylosing spondylitis	0.000148	0.000568	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—ankylosing spondylitis	0.000146	0.000563	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—ankylosing spondylitis	0.000146	0.000563	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—ankylosing spondylitis	0.000146	0.000563	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—ankylosing spondylitis	0.000146	0.000561	CcSEcCtD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000146	0.00294	CbGpPWpGaD
Sirolimus—Rash—Prednisolone—ankylosing spondylitis	0.000145	0.00056	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—ankylosing spondylitis	0.000145	0.000559	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000145	0.000559	CcSEcCtD
Sirolimus—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000145	0.000557	CcSEcCtD
Sirolimus—Headache—Prednisolone—ankylosing spondylitis	0.000144	0.000556	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—ankylosing spondylitis	0.000144	0.000556	CcSEcCtD
Sirolimus—Constipation—Prednisone—ankylosing spondylitis	0.000143	0.000552	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD79A—ankylosing spondylitis	0.000142	0.00287	CbGpPWpGaD
Sirolimus—Confusional state—Methotrexate—ankylosing spondylitis	0.000141	0.000544	CcSEcCtD
Sirolimus—MTOR—Immune System—IL1R2—ankylosing spondylitis	0.000141	0.00285	CbGpPWpGaD
Sirolimus—Dizziness—Triamcinolone—ankylosing spondylitis	0.00014	0.00054	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00014	0.000539	CcSEcCtD
Sirolimus—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00014	0.000539	CcSEcCtD
Sirolimus—Infection—Methotrexate—ankylosing spondylitis	0.000139	0.000536	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000138	0.000532	CcSEcCtD
Sirolimus—Asthenia—Dexamethasone—ankylosing spondylitis	0.000138	0.000532	CcSEcCtD
Sirolimus—Asthenia—Betamethasone—ankylosing spondylitis	0.000138	0.000532	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000137	0.000529	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000137	0.000528	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000137	0.000528	CcSEcCtD
Sirolimus—Nausea—Prednisolone—ankylosing spondylitis	0.000137	0.000527	CcSEcCtD
Sirolimus—Pruritus—Betamethasone—ankylosing spondylitis	0.000136	0.000524	CcSEcCtD
Sirolimus—Pruritus—Dexamethasone—ankylosing spondylitis	0.000136	0.000524	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—ankylosing spondylitis	0.000136	0.000524	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000135	0.000521	CcSEcCtD
Sirolimus—Vomiting—Triamcinolone—ankylosing spondylitis	0.000135	0.000519	CcSEcCtD
Sirolimus—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000135	0.000518	CcSEcCtD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000134	0.00271	CbGpPWpGaD
Sirolimus—Rash—Triamcinolone—ankylosing spondylitis	0.000134	0.000515	CcSEcCtD
Sirolimus—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000134	0.000514	CcSEcCtD
Sirolimus—MTOR—Immune System—ERAP1—ankylosing spondylitis	0.000134	0.0027	CbGpPWpGaD
Sirolimus—Anorexia—Methotrexate—ankylosing spondylitis	0.000134	0.000514	CcSEcCtD
Sirolimus—Rash—Methylprednisolone—ankylosing spondylitis	0.000133	0.000514	CcSEcCtD
Sirolimus—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000133	0.000513	CcSEcCtD
Sirolimus—Headache—Triamcinolone—ankylosing spondylitis	0.000133	0.000512	CcSEcCtD
Sirolimus—Headache—Methylprednisolone—ankylosing spondylitis	0.000133	0.00051	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—ankylosing spondylitis	0.000133	0.00051	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—ankylosing spondylitis	0.000133	0.00051	CcSEcCtD
Sirolimus—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000132	0.000507	CcSEcCtD
Sirolimus—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000132	0.000507	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—HLA-C—ankylosing spondylitis	0.000132	0.00266	CbGpPWpGaD
Sirolimus—Hypotension—Methotrexate—ankylosing spondylitis	0.000131	0.000504	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.00013	0.00263	CbGpPWpGaD
Sirolimus—FGF2—Disease—B3GNT2—ankylosing spondylitis	0.000129	0.00261	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000128	0.000491	CcSEcCtD
Sirolimus—Dizziness—Betamethasone—ankylosing spondylitis	0.000127	0.00049	CcSEcCtD
Sirolimus—Dizziness—Dexamethasone—ankylosing spondylitis	0.000127	0.00049	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—ankylosing spondylitis	0.000127	0.000488	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000126	0.00256	CbGpPWpGaD
Sirolimus—Nausea—Triamcinolone—ankylosing spondylitis	0.000126	0.000485	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000126	0.000484	CcSEcCtD
Sirolimus—Nausea—Methylprednisolone—ankylosing spondylitis	0.000126	0.000484	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000125	0.000481	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—ankylosing spondylitis	0.000125	0.000479	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000123	0.000475	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000123	0.000475	CcSEcCtD
Sirolimus—Vomiting—Betamethasone—ankylosing spondylitis	0.000122	0.000471	CcSEcCtD
Sirolimus—Vomiting—Dexamethasone—ankylosing spondylitis	0.000122	0.000471	CcSEcCtD
Sirolimus—MTOR—Immune System—CARD9—ankylosing spondylitis	0.000122	0.00247	CbGpPWpGaD
Sirolimus—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000122	0.000469	CcSEcCtD
Sirolimus—Rash—Betamethasone—ankylosing spondylitis	0.000121	0.000467	CcSEcCtD
Sirolimus—Rash—Dexamethasone—ankylosing spondylitis	0.000121	0.000467	CcSEcCtD
Sirolimus—Dermatitis—Betamethasone—ankylosing spondylitis	0.000121	0.000467	CcSEcCtD
Sirolimus—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000121	0.000467	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000121	0.000466	CcSEcCtD
Sirolimus—Headache—Betamethasone—ankylosing spondylitis	0.000121	0.000464	CcSEcCtD
Sirolimus—Headache—Dexamethasone—ankylosing spondylitis	0.000121	0.000464	CcSEcCtD
Sirolimus—Asthenia—Prednisone—ankylosing spondylitis	0.00012	0.000463	CcSEcCtD
Sirolimus—Pain—Methotrexate—ankylosing spondylitis	0.00012	0.000461	CcSEcCtD
Sirolimus—Pruritus—Prednisone—ankylosing spondylitis	0.000119	0.000457	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL1A—ankylosing spondylitis	0.000116	0.00235	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD40LG—ankylosing spondylitis	0.000116	0.00234	CbGpPWpGaD
Sirolimus—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000115	0.000444	CcSEcCtD
Sirolimus—Diarrhoea—Prednisone—ankylosing spondylitis	0.000115	0.000442	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000115	0.000441	CcSEcCtD
Sirolimus—Nausea—Dexamethasone—ankylosing spondylitis	0.000114	0.00044	CcSEcCtD
Sirolimus—Nausea—Betamethasone—ankylosing spondylitis	0.000114	0.00044	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000112	0.00226	CbGpPWpGaD
Sirolimus—Dizziness—Prednisone—ankylosing spondylitis	0.000111	0.000427	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000111	0.000426	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000111	0.000426	CcSEcCtD
Sirolimus—EIF4E—Immune System—HLA-B—ankylosing spondylitis	0.00011	0.00222	CbGpPWpGaD
Sirolimus—Vomiting—Prednisone—ankylosing spondylitis	0.000107	0.00041	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000106	0.00214	CbGpPWpGaD
Sirolimus—Rash—Prednisone—ankylosing spondylitis	0.000106	0.000407	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—ankylosing spondylitis	0.000106	0.000406	CcSEcCtD
Sirolimus—Headache—Prednisone—ankylosing spondylitis	0.000105	0.000404	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000105	0.00212	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-C—ankylosing spondylitis	0.000103	0.00209	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000103	0.000397	CcSEcCtD
Sirolimus—EIF4E—Immune System—HLA-A—ankylosing spondylitis	0.000102	0.00206	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000102	0.00206	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000101	0.00204	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—ankylosing spondylitis	0.000101	0.000387	CcSEcCtD
Sirolimus—Nausea—Prednisone—ankylosing spondylitis	9.96e-05	0.000383	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—ankylosing spondylitis	9.91e-05	0.000382	CcSEcCtD
Sirolimus—EIF4E—Immune System—CRP—ankylosing spondylitis	9.72e-05	0.00196	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD79A—ankylosing spondylitis	9.64e-05	0.00195	CbGpPWpGaD
Sirolimus—MTOR—Disease—B3GNT2—ankylosing spondylitis	9.59e-05	0.00194	CbGpPWpGaD
Sirolimus—Diarrhoea—Methotrexate—ankylosing spondylitis	9.58e-05	0.000369	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.34e-05	0.00189	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—TLR4—ankylosing spondylitis	9.32e-05	0.00188	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CRP—ankylosing spondylitis	9.27e-05	0.00187	CbGpPWpGaD
Sirolimus—Dizziness—Methotrexate—ankylosing spondylitis	9.26e-05	0.000357	CcSEcCtD
Sirolimus—FGF2—Immune System—IL1RN—ankylosing spondylitis	8.98e-05	0.00181	CbGpPWpGaD
Sirolimus—Vomiting—Methotrexate—ankylosing spondylitis	8.91e-05	0.000343	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—TLR4—ankylosing spondylitis	8.89e-05	0.0018	CbGpPWpGaD
Sirolimus—Rash—Methotrexate—ankylosing spondylitis	8.83e-05	0.00034	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—ankylosing spondylitis	8.82e-05	0.00034	CcSEcCtD
Sirolimus—Headache—Methotrexate—ankylosing spondylitis	8.78e-05	0.000338	CcSEcCtD
Sirolimus—Nausea—Methotrexate—ankylosing spondylitis	8.32e-05	0.00032	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—PTGER4—ankylosing spondylitis	8.19e-05	0.00166	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP3—ankylosing spondylitis	7.95e-05	0.00161	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD79A—ankylosing spondylitis	7.88e-05	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.86e-05	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HLA-B—ankylosing spondylitis	7.79e-05	0.00157	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-C—ankylosing spondylitis	7.67e-05	0.00155	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.48e-05	0.00151	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.93e-05	0.0014	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—B3GNT2—ankylosing spondylitis	6.9e-05	0.0014	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HLA-A—ankylosing spondylitis	6.9e-05	0.00139	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CRP—ankylosing spondylitis	6.88e-05	0.00139	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1RN—ankylosing spondylitis	6.66e-05	0.00135	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TLR4—ankylosing spondylitis	6.6e-05	0.00133	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	6.58e-05	0.00133	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1A—ankylosing spondylitis	6.46e-05	0.00131	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—ankylosing spondylitis	6.42e-05	0.0013	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	6.34e-05	0.00128	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTGER4—ankylosing spondylitis	6.21e-05	0.00125	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-B—ankylosing spondylitis	6.11e-05	0.00124	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD79A—ankylosing spondylitis	5.85e-05	0.00118	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP3—ankylosing spondylitis	5.83e-05	0.00118	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-A—ankylosing spondylitis	5.66e-05	0.00114	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CRP—ankylosing spondylitis	5.4e-05	0.00109	CbGpPWpGaD
Sirolimus—FGF2—Disease—HLA-A—ankylosing spondylitis	5.23e-05	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR4—ankylosing spondylitis	5.18e-05	0.00105	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1A—ankylosing spondylitis	4.8e-05	0.000969	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—ankylosing spondylitis	4.77e-05	0.000964	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—ankylosing spondylitis	4.75e-05	0.000961	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTGER4—ankylosing spondylitis	4.6e-05	0.000931	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	4.58e-05	0.000926	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-B—ankylosing spondylitis	4.54e-05	0.000917	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP3—ankylosing spondylitis	4.42e-05	0.000893	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-A—ankylosing spondylitis	4.2e-05	0.000849	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CRP—ankylosing spondylitis	4.01e-05	0.00081	CbGpPWpGaD
Sirolimus—MTOR—Disease—HLA-A—ankylosing spondylitis	3.88e-05	0.000784	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR4—ankylosing spondylitis	3.84e-05	0.000777	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.46e-05	0.000699	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP3—ankylosing spondylitis	3.28e-05	0.000663	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.25e-05	0.000657	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.13e-05	0.00043	CbGpPWpGaD
